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Research article MUC1-associated proliferation signature predicts 
outcomes in lung adenocarcinoma patients
Dhara M MacDermed*†1, Nikolai N Khodarev†2, Sean P Pitroda2, Darrin C Edwards3, Charles A Pelizzari2, Lei Huang4, 
Donald W Kufe†4 and Ralph R Weichselbaum†2
Abstract
Background: MUC1 protein is highly expressed in lung cancer. The cytoplasmic domain of MUC1 (MUC1-CD) induces 
tumorigenesis and resistance to DNA-damaging agents. We characterized MUC1-CD-induced transcriptional changes 
and examined their significance in lung cancer patients.
Methods: Using DNA microarrays, we identified 254 genes that were differentially expressed in cell lines transformed 
by MUC1-CD compared to control cell lines. We then examined expression of these genes in 441 lung 
adenocarcinomas from a publicly available database. We employed statistical analyses independent of clinical 
outcomes, including hierarchical clustering, Student's t-tests and receiver operating characteristic (ROC) analysis, to 
select a seven-gene MUC1-associated proliferation signature (MAPS). We demonstrated the prognostic value of MAPS 
in this database using Kaplan-Meier survival analysis, log-rank tests and Cox models. The MAPS was further validated for 
prognostic significance in 84 lung adenocarcinoma patients from an independent database.
Results: MAPS genes were found to be associated with proliferation and cell cycle regulation and included CCNB1, 
CDC2, CDC20, CDKN3, MAD2L1, PRC1 and RRM2. MAPS expressors (MAPS+) had inferior survival compared to non-
expressors (MAPS-). In the initial data set, 5-year survival was 65% (MAPS-) vs. 45% (MAPS+, p < 0.0001). Similarly, in the 
validation data set, 5-year survival was 57% (MAPS-) vs. 28% (MAPS+, p = 0.005).
Conclusions: The MAPS signature, comprised of MUC1-CD-dependent genes involved in the control of cell cycle and 
proliferation, is associated with poor outcomes in patients with adenocarcinoma of the lung. These data provide 
potential new prognostic biomarkers and treatment targets for lung adenocarcinoma.
Background
Lung cancer is the most common cancer worldwide and
is the leading cause of cancer-related death in the United
States. Approximately 213 000 new diagnoses and over
160 000 deaths from lung cancer occur annually in the
United States [1]. About 85% of lung cancers are non-
small cell histology (NSCLC), including lung adenocarci-
noma, which is the most common lung cancer type [2].
Treatment of early and intermediate stage NSCLC usu-
ally involves surgery. Most patients with localized lung
cancer are now treated with adjuvant platinum-based
chemotherapy, which provides a survival advantage [3].
The utility of postoperative radiation is controversial and
subsets of pa tients ha ve been pr oposed t o benefit, but
clear clinical and/or molecular identification of patients
who may benefit from postoperative radiation remains
uncharacterized. In contrast, recently identified molecu-
lar classifiers based on statistically derived gene signa-
tures may facilitate the selection of patients who will
benefit from adjuvant chemotherapy [4,5]. Nonetheless,
no prognostic or predictive signature for NSCLC is regu-
larly used in a clinical setting.
Mucin 1 (MUC1) is a protein heterodimer that is over-
expressed in lung cancers [6]. MUC1 consists of two sub-
units, an N-terminal extracellular subunit (MUC1-N) and
a C-terminal transmembrane subunit (MUC1-C). Over-
expression of MUC1 is sufficient for the induction of
anchorage independent growth and tumorigenicity [7].
Other studies have shown that the MUC1-C cytoplasmic
domain is responsible for the induction of the malignant
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phenotype and that MUC1-N is dispensable for transfor-
mation [8]. Overexpression of MUC1 also confers resis-
tance to stress-induced cell death, conferred by exposure
to certain genotoxic anticancer agents [9-11]. In this
regard, targeting of the MUC1-CD subunit to the nucleus
attenuates p53-mediated apoptosis in response to DNA
damage [12]. Notably, MUC1 protein expression has been
associated with poor prognosis in NSCLC [13,14]. Taken
together, these data have provided a rationale for an in-
depth analysis of transcriptional programs induced by the
MUC1-C cytoplasmic domain (MUC1-CD).
We previously reported a method for analysis of biolog-
ically derived data relevant to the identification of expres-
sional signatures with prognostic and predictive value
[15-17]. We used this approach to identify a MUC1-
induced Tumorigenesis Signature (MTS) based on the
profiling of MUC1-CD-transfected xenografts grown in
nude mice [18]. The MTS was derived through compari-
son of MUC1-CD-transfected tumors in vivo and the cor-
responding cell lines grown in vitro. We hypothesized
that such a comparison would detect the genes differen-
tially expressed as a result of tumor-stromal interactions.
Indeed, the major functional groups of genes represented
in MTS were cell motility, metastasis and angiogenesis. In
the current report, we focused on the in vitro profiling of
3Y1 cell lines transfected with MUC1-CD compared with
mock-transfected cells to define "intrinsic" MUC1-CD-
dependent transcriptional changes without stromal
effects. Using this approach, we expected to identify
MUC1-CD-dependent genes intrinsically associated with
an aggressive tumor behavior. Here we report that a
MUC1-Associated Proliferation Signature (MAPS) com-
prised of genes that mediate cell cycle control and mitotic
spindle assembly has significant prognostic value in lung
adenocarcinoma patients. Importantly, the MAPS is the
first biologically derived gene signature comprised
uniquely of MUC1-induced genes involved in the control
of cell cycle and proliferation.
Methods
Cells and culture conditions
Rat 3Y1 embryonic fibroblasts were transfected by an
empty vector (3Y1/Vector) and by the cytoplasmic
domain of MUC1 (3Y1/MUC1-CD) as previously
described [19]. Transfected 3Y1 cells were cultured in
DMEM media with 10% heat-inactivated fetal bovine
serum, 100 units/mL penicillin, 100 μg/mL streptomycin,
and 2 mmol/L L-glutamine and maintained at 37°C in a
humidified environment containing 5% CO2.
RNA extraction and purification
RNA was collected and purified from confluent 3Y1/Vec-
tor and 3Y1/MUC1-CD cell cultures using TRIzol
reagent (Invitrogen Life Sciences, Carlsbad, CA, USA)
according to the manufacturer's instructions. Further
purification was performed using a combination of
RNeasy spin columns and TRIzol reagent, as we previ-
ously described [20]. The quality of samples was assessed
using gel electrophoresis in 1.8% agarose and spectropho-
tometry, and samples of high quality were transferred to
the Functional Genomics Facility of The University of
Chicago for labeling and hybridization with GeneChip®
Rat Genome 230 2.0 Arrays (Affymetrix, Santa Clara,
CA, USA).
DNA microarray data collection and analysis
The selection and analysis of genes differentially
expressed in 3Y1/Vector cells compared to 3Y1/MUC1-
CD cells in vitro was based on previously described
methods. Briefly, each array was hybridized with a pooled
sample normalized to total RNA and consisting of RNA
obtained from 3 independent cell lines. After data
retrieval and scaling using MAS 5.0 Microarray Suite
software (Affymetrix, Santa Clara, CA, USA), data were
rescaled using "global median normalization" across the
entire dataset [21] and filtrated using a multi-step filtra-
tion method, which involves the application of Receiver
Operating Characteristic analysis (ROC analysis) for the
estimation of cut-off signal intensity values [22]. Subse-
quent analysis was based on pair-wise comparisons of
duplicated arrays (3Y1/Vector in vitro vs. 3Y1/MUC1-CD
in vitro) using Significance Analysis of Microarrays
(SAM) version 3.0 (Stanford University Labs, http://
www-stat.stanford.edu/~tibs/SAM/). Differentially
expressed probe set IDs were selected using a 2.0-fold
induction cut-off level with selection of delta values mini-
mizing the False Discovery Ratio. Probe set IDs were gene
annotated and functionally designated using Ingenuity
Pathways Analysis (IPA, Ingenuity®  Systems, http://
www.ingenuity.com).
Array data are deposited in GEO, accession #
GSE14337 (MUC1-induced transcriptional alterations in
rat 3Y1 embryonic fibroblasts [Rattus norvegicus]), http:/
/www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE14337.
Collection of publicly available cancer databases
Two publicly available cancer databases containing
expressional data from adenocarcinoma of the lung were
analyzed to determine whether the MUC1-CD-depen-
dent genes have predictive value in determining the out-
come for each patient sample. The first database was
obtained from a multicenter consortium (University of
Michigan Cancer Center, Moffitt Cancer Center, Memo-
rial Sloan-Kettering Cancer Center, and the Dana-Farber
Cancer Institute) consisting of surgically resected lung
adenocarcinoma specimens from 442 patients [23]. These
patients presented with stage I to III disease and wereMacDermed et al. BMC Medical Genomics 2010, 3:16
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treated without pre-operative chemotherapy or radiation.
A subset of patients (n = 108) had adjuvant treatment
with radiation and/or chemotherapy. One patient was
excluded from survival analysis because survival data was
missing. An independent database was used for confir-
mation of our findings [24]. Analysis included 84 quality-
controlled cases with at least 40% tumor cellularity, ade-
nocarcinoma only (no mixed histology), and available
survival data [25]. These patients were treated with pri-
mary surgical resection and data regarding adjuvant ther-
apy were not available.
Statistical analyses
For initial analysis, the raw signal intensity for each probe
set ID of interest for each patient was normalized to the
median value of the probe set ID across the entire data-
base and subsequently log2-transformed. For subgroup
analyses, the raw data were divided into subgroups and
normalization was performed across each subgroup.
Multiple probe set IDs for a given gene were averaged for
each patient sample to obtain a representative expression
value for each gene.
Clustering and survival analyses were performed using
JMP 7.1 (SAS Institute Inc. Cary, NC, USA). Expression
data were clustered using hierarchical clustering via
Ward's method to visualize gene expression patterns
across each database. Genes having uniform expression
across the patient samples in the initial clustering of
genes were eliminated and not used for further analyses
(87 out of 254 genes were eliminated in this manner).
Before any further reduction of the gene set, survival
analysis was performed based on clustering of the biolog-
ically derived genes. To determine whether clustering
based on the differential expression of the MUC1-CD-
induced genes could identify patients with decreased sur-
vival, Kaplan-Meier survival analysis was performed on
clusters defined by k-means clustering. The k-means
clustering was performed using a predetermined number
of clusters (k = 2) and a log-rank test was used to estimate
significance of survival differences between the two clus-
ters. Subsequently, a smaller number of genes was
selected from this gene set for practical application. An F-
test was further used to test the null hypothesis of no dif-
ference in variance for each gene between the two patient
clusters. Results of the F-test were further entered into an
unpaired 2-tailed Student's t-test to test the null hypothe-
sis of no difference in the magnitude of gene expression
of each gene between the two patient clusters. The alpha
level for each t-test was 0.05. As a result, we obtained a
set of probes comprising 42 unique genes. Once the final
signature was selected using ROC analysis (see full details
in subsequent ROC analysis section), the mean expres-
sion across genes in the signature was calculated as a rela-
tive expression score [17,18]. A positive value (> 0)
designated the patient as MAPS+. Kaplan-Meier survival
statistics were performed and log-rank tests were used to
test the null hypothesis of no difference in survival func-
tions between MAPS+ and MAPS- patients. We then
performed univariate and multivariate analysis using a
Cox proportional hazards model to evaluate prognostic
factors, including MAPS. Clinical features such as tumor
stage, lymph node involvement and histological grade
were included in these analyses as binary variables: T1-
T2 vs. T3-T4, nodes involved (N1-2) vs. uninvolved (N0),
and intermediate or high grade vs. low grade. For each
clinical variable, binary categories were selected based on
maximum prognostic significance for overall survival in
our dataset.
Receiver operating characteristic (ROC) analysis
To derive the final 7-gene signature, ROC analysis was
used to assign an AUC value to each gene as a single fea-
ture. A ROC curve is a graphical plot of the sensitivity vs.
(1 - specificity) for a binary classifier system as its dis-
crimination threshold is varied. The area under the ROC
curve (AUC) is a widely-used performance metric for the
binary classifier system being evaluated. We used ROC
analysis to assign area under the curve (AUC) scores to
evaluate the ability of each individual gene in the set to
classify patients into the two groups (expressors vs. non-
expressors - see [26]). This analysis was performed inde-
pendent of survival data. AUC scores were assigned to
each gene by applying the PROPROC program [27]. We
selected those genes with an AUC score above 0.95, rep-
resenting a probability of error under 5%, which resulted
in a subset of 7 genes. The algorithm by which we nar-
rowed our gene set down to 7 genes is summarized in
Additional File 1, Figure S1. Six of the seven genes had
matching expressional data in the validation dataset
(PRC1 was absent in this database due to the differences
in array platforms).
Results
1. MUC1 is associated with changes in the expression of 
genes that regulate cellular growth and proliferation
Differences in gene expression were identified by com-
paring MUC1-CD-transformed 3Y1 cells to those trans-
fected with a control vector and grown in vitro. Gene
expression analysis using Significance Analysis of
Microarrays (SAM) yielded 254 differentially expressed
genes in MUC1-CD-transfected cells, shown in Figure 1A
and Additional File 2, Table S1. Functional gene analysis
using Ingenuity Pathway Analysis (IPA) of the 254 genes
identified cellular growth and proliferation as the most
significantly represented function (91 molecules, Fisher's
exact p = 1.26 × 10-8). Furthermore, IPA functional net-
work analysis demonstrated that the most statistically sig-
nificant networks representing the web of interactionsMacDermed et al. BMC Medical Genomics 2010, 3:16
http://www.biomedcentral.com/1755-8794/3/16
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among these genes indeed mediate cellular growth and
proliferation (Fisher's exact p = 10-44) and cell cycle and
cellular assembly (Fisher's exact p = 10-41) as shown in
Figure 1B and Additional File 3, Table S2. Taken together,
these data indicate that MUC1-CD-induced transforma-
tion is associated with distinct changes in gene expres-
sion associated with the control of cellular growth and
proliferation.
2. Development of a MUC1-dependent, proliferation-
associated molecular signature
To test the hypothesis that differential expression of the
254 genes regulated by MUC1-CD is linked to poor prog-
nosis, a large, multi-institutional lung adenocarcinoma
database of 442 cases [23] was utilized. K-means cluster-
ing based on expression of these 254 genes was used to
divide patients into two groups (Figure 2A). Kaplan-
Meier survival analysis of patient groups defined by k-
means clustering demonstrated significant 5-year sur-
vival differences between groups (47.0% vs. 64.6%, log-
rank p < 0.0001, Figure 2B). These data demonstrate that
differential expression of MUC1-CD-associated genes is
associated with poor outcome of lung adenocarcinoma
patients.
We used a combination of parametric statistics and
receiver operating characteristic (ROC) analysis to
reduce the size of this gene set and identify those genes
whose expression was most closely linked to the prognos-
tic clusters identified using the entire 254 gene set. Forty-
two genes were initially identified using parametric statis-
tics (see Table 1). Network analysis using IPA showed that
these genes form a network representing DNA replica-
tion/cell cycle, recombination and repair (e.g. CCNB1,
CDC2, CDC20, CDKN3, MAD2L1 and MCM7). For
more details on this network, see Additional File 4, Figure
S2. Similar data were obtained by IPA-based analysis of
Figure 1 Differentially expressed genes in MUC1 transfected cells. A. Expressional clustering of genes expressed at least two-fold differently in 
(a) MUC1 transfected 3Y1 cells compared with (b) cells transfected with empty vector. B. A functional network involving many of these upregulated 
(pink) and downregulated (green) genes. Functions include cell cycle, cellular assembly and organization, DNA replication, recombination and repair.MacDermed et al. BMC Medical Genomics 2010, 3:16
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the most significant functions of these 42 genes, which
represented the same pathways (p = 1.5 × 10-6; Fisher's
exact test). Seven genes, including CCNB1, CDC20,
CDKN3, CDC2, MAD2L1, PRC1, and RRM2, were iden-
tified through ROC analysis (see Table 2). Representative
ROC curves for the top three genes (CCNB1, CDC20 and
CDKN3) are shown in Figure 3. Given that IPA analysis of
these genes demonstrated significant functions in the
regulation of cell proliferation, cell cycle and chromo-
some segregation, we designated this 7-gene set as the
MUC1-Associated Proliferation Signature (MAPS).
3. MAPS is associated with poor prognosis in lung 
adenocarcinoma
Induction of the MAPS by MUC1-CD and its association
with cell proliferation suggested that expression of this
signature might identify an aggressive tumor phenotype.
To test this hypothesis, we investigated two independent
expressional databases of lung adenocarcinomas (see
Materials and Methods). Expression of the MAPS in 442
lung adenocarcinomas [23] demonstrated distinct differ-
ences in expression across patients (Figure 4). Impor-
tantly, patients expressing the MAPS (MAPS+) had a
significantly worse prognosis (5-year survival 45% vs.
65%, log-rank p < 0.0001, 5-year disease free survival 41%
vs. 49%, log-rank p = 0.003, Figure 4) compared to non-
expressors (MAPS-).
To evaluate the prognostic value of the MAPS, a multi-
variate Cox proportional analysis, including tumor stage,
tumor grade, lymph node involvement and MAPS
expression, was performed as described in the Materials
and Methods. Distribution of clinical characteristics in
the study population is shown in Table 3. The data pre-
s e n t e d  i n  T a b l e  4  d e m o n s t r a t e  t h a t  e x p r e s s i o n  o f  t h e
MAPS is an independent prognostic factor for overall
survival (HR = 1.6, p = 0.024). Lymph node involvement
was the most significant prognostic factor for overall sur-
vival based on univariate and multivariate analysis (multi-
variate HR 2.6, p = 2.29 × 10-11). Furthermore, expression
of the MAPS enhanced the prognostic ability of lymph
node status. In this regard, the 5-year survival for MAPS-
/node-negative was significantly better than MAPS+/
node-negative (71% vs. 59%, p = 0.0135) and survival for
MAPS-/node-positive was significantly better than
MAPS+/node-positive (46% vs. 22%, p = 0.0003) (Figure
5). Using an independent database of 84 patients [25] for
validation of these results, the data show that patients
stratified by expression of these genes also showed signif-
icant differences in overall survival (5-year survival 57%
in MAPS- vs. 28% in MAPS+, log-rank p = 0.005, Figure
6). These data thus support that expression of the genes
comprising the MAPS has clinical relevance in the identi-
fication of lung adenocarcinoma patients with poor prog-
nosis.
Discussion
Previously we found that the cytoplasmic domain of
MUC1 (MUC1-CD) induces multiple, stable transcrip-
tional changes in transfected cells. We investigated these
changes in in vivo models and identified two unique
MUC1-CD-dependent expressional signatures. One,
which we denoted as the MTS (MUC1 Tumorigenesis
Figure 2 Expressional clustering based on 254 MUC1-CD-associated genes is associated with survival of lung adenocarcinoma patients. A. 
3-dimensional representation of the centroids generated by K-means clustering. Each point forming a cloud surrounding the centroid represents a 
patient assigned to the cluster corresponding to the centroid. B. 5-year survival of patients assigned to each cluster.MacDermed et al. BMC Medical Genomics 2010, 3:16
http://www.biomedcentral.com/1755-8794/3/16
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Table 1: 42 genes selected based on their differential 
expression between prognostic groups.
Gene Symbol Gene Title
ALDH6A1 aldehyde dehydrogenase 6 
family
BECN1 beclin 1
BTG3 BTG family
BUB1 BUB1 budding uninhibited by 
benzimidazoles 1 homolog 
(yeast)
CCNB1 cyclin B1
CDC2 cell division cycle 2
CDC20 cell division cycle 20 homolog (S. 
cerevisiae)
CDKN3 cyclin-dependent kinase 
inhibitor 3
CKAP4 cytoskeleton-associated 
protein 4
CSRP2 cysteine and glycine-rich 
protein 2
DEPDC1 DEP domain containing 1
DHCR24 24-dehydrocholesterol 
reductase
DNAJC9 DnaJ (Hsp40) homolog
DUSP6 dual specificity phosphatase 6
EDEM1 ER degradation enhancer
EHD4 EH-domain containing 4
ELOVL6 ELOVL family member 6
ERN1 endoplasmic reticulum to 
nucleus signaling 1
ETV4 ets variant gene 4 (E1A enhancer 
binding protein
FRS2 fibroblast growth factor receptor 
substrate 2
FUCA1 fucosidase
H2AFZ H2A histone family
ID1 inhibitor of DNA binding 1
KAZALD1 Kazal-type serine peptidase 
inhibitor domain 1
LRRC17 leucine rich repeat containing 17
MAD2L1 MAD2 mitotic arrest deficient-
like 1 (yeast)
MCM7 minichromosome maintenance 
complex component 7
OLFML3 olfactomedin-like 3
PFN2 profilin 2
PGCP plasma glutamate 
carboxypeptidase
PJA2 praja 2
PRC1 protein regulator of 
cytokinesis 1
PTPRF protein tyrosine phosphatase
RRM2 ribonucleotide reductase M2 
polypeptide
SC5DL sterol-C5-desaturase (ERG3 
delta-5-desaturase homolog
SDC2 syndecan 2
SLC16A1 solute carrier family 16
SLC20A1 solute carrier family 20 
(phosphate transporter)
SSX2IP synovial sarcoma
TRIM25 tripartite motif-containing 25
TXNDC13 thioredoxin domain 
containing 13
Table 1: 42 genes selected based on their differential 
expression between prognostic groups. (Continued)MacDermed et al. BMC Medical Genomics 2010, 3:16
http://www.biomedcentral.com/1755-8794/3/16
Page 7 of 12
Signature), was identified in vivo and reflected the inter-
actions of tumor cells with the host microenvironment,
as was evidenced by the activation of genes involved in
angiogenesis and extracellular matrix signaling [18]. A
second expressional signature representing lipid and cho-
lesterol metabolism was also identified in the context of
tumor-stromal interactions [17]. Therefore, in the cur-
rent report, we focused on the detection of MUC1-CD-
dependent transcriptional changes unique to oncogenic
cells. We hypothesized that these "intrinsic" changes
would be important for MUC1-CD signaling leading to
oncogenesis and may be connected with the fundamental
mechanisms of the malignant transformation. In this
regard, we profiled MUC1-CD-transformed cells grown
in vitro, without any influences from the host stroma.
In the current report, we describe a MUC1-Associated
Proliferation Signature (MAPS) that provides indepen-
dent prognostic information, adding to standard patho-
logical evaluation and clinical staging of lung
adenocarcinoma. This signature was derived from the set
of genes initially detected in an experimental system as
upregulated by MUC1-CD in vitro and potentially
involved in a highly oncogenic phenotype [18]. The
MAPS is distinct from our previously reported MUC1-
related signature (MTS, [18]) and was identified using a
contrasting experimental approach. The major functional
groups of differentially expressed genes in vitro repre-
Table 3: Clinical variables in 441 lung adenocarcinoma patients included in survival analysis.
Clinical variable Categories Number of patients
T stage T1-2 399
T3-4 40
N stage Nodes uninvolved (N0) 299
Nodes involved (N1-2) 139
Tumor grade Low grade (1) 60
Intermediate or high grade (2-3) 374
Our classifier (MAPS) MAPS- 229
MAPS+ (Expressor) 211
Table 2: Top scoring genes from ROC analysis.
Gene Symbol Gene Title Pathway AUC score
CDC20 Cell division cycle 20 Cell cycle 0.99
RRM2 Ribonucleotide reductase M2 polypeptide DNA synthesis 0.98
CCNB1 cyclin B1 Cell cycle G1 to S 0.98
MAD2L1 MAD2 mitotic arrest deficient-like 1 (yeast) Mitotic spindle checkpoint 0.98
PRC1 protein regulator of cytokinesis 1 Mitotic spindle assembly 0.97
CDC2 cell division cycle 2 Cell Cycle G1 to S and G2 to M 0.97
CDKN3 cyclin-dependent kinase inhibitor 3 Cell Cycle 0.97
A high AUC score indicates a strong ability to distinguish between groups (in this case, to identify expressors of our genes of interest).MacDermed et al. BMC Medical Genomics 2010, 3:16
http://www.biomedcentral.com/1755-8794/3/16
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sented cellular growth, proliferation and cell cycle con-
trol. In comparison, the MTS was derived from genes
highly enriched by functional groups representing cell
motility, metastasis and angiogenesis. We believe that
these results demonstrate important differences between
the intrinsic properties of tumor cells and the properties
that are determined by tumor-stromal interactions. Inter-
estingly, only two genes (CDC20 and RRM2) were com-
mon between both signatures, perhaps indicating that, at
least in our experimental system, expression of these two
genes is independent of the host microenvironment.
All the genes that comprise the MAPS are related to cell
cycle control and proliferation. For instance, CDC20
(homolog of S. cerevisiae cell division cycle 20 protein)
directly binds to and activates anaphase-promoting com-
plex (APC), which leads to ubiquitination and degrada-
tion of cyclin B (CCNB1) and therefore promotes the
onset of anaphase and mitotic exit [28]. The APC/CDC20
complex is under negative control of MAD2L1 (human
homolog of S. Cerevisiae MAD2) and BUB1 (see Table 1).
Also, PRC1 (protein regulating cytokinesis 1) is a human
homolog of S. cerevisiae Ase1, which is involved in spin-
dle formation and also promotes anaphase and mitotic
exit [29]. CDC2 (cell division cycle 2), or CDK1 (cyclin-
dependent kinase 1), is a catalytic subunit of a protein
kinase complex, called the M-phase promoting factor,
Figure 3 ROC curves analyzing the use of expression levels of individual genes, CCNB1, CDC20 and CDKN3, to accurately assign patients 
to prognostic groups.MacDermed et al. BMC Medical Genomics 2010, 3:16
http://www.biomedcentral.com/1755-8794/3/16
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formed with cyclin B1 (CCNB1) that induces entry into
mitosis [30]. CDC2 phosphorylates securin, which is
another target of APC/CDC20 and is an inhibitor of sepa-
rase-protease, responsible for the cleavage of sister chro-
matid cohesions. CDC2-dependent phosphorylation of
securin protects it from APC/CDC20-induced ubiquit-
ination and degradation [31]. CDKN3 (cyclin-dependent
kinase inhibitor 3) is a dual-specificity protein phos-
phatase that interacts with CDC2 and CDK2 and inhibits
their activity [32]. These data show that six of the seven
genes comprising MAPS not only belong to a cell cycle-
related functional group but represent a specific pathway
of interacting proteins responsible for anaphase control,
chromosome segregation and mitotic entrance/exit (see
also Figure 1B). RRM2 (ribonucleotide reductase, M2
subunit) encodes the small subunit (R2) of ribonucleotide
reductase, the heterodimeric enzyme that catalyzes the
rate-limiting step in deoxyribonucleotide synthesis.
Using siRNA screening, Kittler et al. [33] identified 37
genes required for cell division, one of which was RRM2.
There is substantial literature indicating that the genes
in MAPS are co-expressed and are involved in tumori-
genesis and cancer progression. Five of seven MAPS
genes are upregulated in immortalized breast cancer cell
lines compared to primary breast tumor cell cultures
(CDC2, CDC20, CDKN3, MAD2L1 and RRM2) [34] and
all seven MAPS genes are upregulated in response to
infection of HPV-18, a virus associated with cervical can-
cer, in keratinocytes [35]. All seven were also found to be
co-expressed with E2F, which is expressed in breast can-
cer compared with normal breast tissue and is elevated
during the G2/M transition [36]. This suggests a possible
role for E2F inhibitors in treating poor-prognosis cancers
that express MAPS. All seven MAPS genes are downreg-
ulated in response to Brd4 transfection in a mouse mam-
mary cell line and are included in a 141-gene prognostic
signature based on differential expression in this cell line.
Expression of this signature correlated with prognosis in
five separate human breast cancer cohorts [37]. This is
one of many published results from tumor expression
profiling experiments which have linked increased
expression of genes from common pathways involved in
cell growth and proliferation to poor outcomes in cancer
patients [38]. A meta-signature was identified consisting
of sixty-nine genes expressed more in high-grade com-
pared to low-grade tumors in eight separate microarray
analyses spanning seven types of cancer including lung
adenocarcinoma [39]. These included many genes associ-
ated with cell proliferation, including five of the seven
genes in our abbreviated MAPS signature: CCNB1,
CDC2, CDC20, CDKN3 and MAD2L1. Thus, MAPS
reflects a pattern of gene expression associated with high-
Table 4: Univariate and multivariate analysis of clinical variables affecting 5-year survival of lung cancer patients, 
including our classifier, with hazard ratios (HR).
Clinical variable Comparison p-value (univariate) p-value (multivariate) HR
T stage T1-2 vs. T3-4 1 × 10-7 1.77 × 10-5 2.6
N stage Nodes uninvolved (N0) 
vs. Nodes involved 
(N1-2)
2.84 × 10-12 2.29 × 10-11 2.8
Tumor grade Low grade (1) vs. 
intermediate or high 
grade (2-3)
0.12 0.37 1.3
Our classifier (MAPS) MAPS- vs. MAPS+ 
(Expressor)
4.66 × 10-6 0.0001 1.8
Statistically significant results are bolded.
Figure 4 Expression of genes in the MUC1-Associated Prolifera-
tion Signature (MAPS). Survival and disease-free survival for expres-
sors of the signature (MAPS+, n = 212) compared with non-expressors 
(MAPS-, n = 229).MacDermed et al. BMC Medical Genomics 2010, 3:16
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grade cancers, but having greater prognostic significance
than histological grade in our results.
Current data of Whitfield et al. [38] indicate that prolif-
eration-associated genes can be considered not only as
common prognostic/predictive markers in different can-
cers, but also as promising targets for anti-cancer therapy.
Among the genes comprising MAPS, at least two are tar-
gets of known drugs. These are hydroxyurea for RRM2
and flavopiridol and staurosporin (UCN-01) for CDK1
(CDC2). In addition, taxol, which affects microtubule for-
mation and blocks mitosis at the G2/M transition, may
have interactions with 6 of 7 gene products included in
MAPS. RRM2 is also a target that may be used to potenti-
ate chemotherapy. Kittler et al. [33] demonstrated that
silencing of RRM1 and RRM2, which encode the large
and small subunits of the human ribonucleotide
reductase (RNR) complex, respectively, markedly
enhanced the cytotoxicity of the topoisomerase I (Top1)
inhibitor camptothecin (CPT). Silencing of RRM2 was
also found to enhance DNA damage as measured by γ-
H2AX. Upregulation in RRM2 expression levels suggests
an active role for RNR in the cellular response to DNA
damage that could potentially be exploited as strategy for
enhancing the efficacy of Top1 inhibitors [40]. The
MUC1-CD is also involved in the control of DNA damage
response [41]. The data presented in the current report
suggest that this control may be associated with a set of
genes regulating G2/M transition and exit from mitosis
through the network of reactions connected with spindle
formation and chromosome segregation.
Many existing biomarkers that have been identified for
non-small-cell lung cancer indicate the presence of dis-
ease, as in screening or recurrence. The genes in the
MAPS are, however, potential biomarkers of prognosis
and could help guide treatment in patients with a new
diagnosis of primary lung cancer. There are cytokeratin
biomarkers that have been studied which show evidence
of prognostic significance in lung adenocarcinoma,
including CYFRA 21-1, TPA and TPS [42]. These bio-
markers are detected on the protein levels in relatively
high concentrations from freshly prepared tissues. Our
signature has the potential to be measured by PCR at
picogram levels both in frozen tissues and paraffin-
embedded archival samples. Further prospective investi-
gations are needed to compare potential protein and
RNA-based biomarkers, which might be complementary
to each other.
Conclusions
These data indicate new insights into the mechanisms
through which MUC1-CD performs its DNA damage-
response and tumorigenic functions. They also suggest
targets that can be accessed for tumor suppression/sensi-
tization to genotoxic treatments in a MUC1-CD-depen-
dent pathway. Therefore, the MUC1-Associated
Proliferation Signature (MAPS) described in the current
report not only serves as a new classifier, but also sheds
light on the mechanisms of MUC1-CD-associated tum-
origenesis and suggests potential gene products and
drugs for targeted cancer therapy.
Additional material
Additional File 1 Figure S1. Algorithm used to select a short signature 
from our biologically derived set of genes correlated with MUC1 transfec-
tion.
Additional File 2 Table S1. 254 genes differentially expressed in MUC1 
transfected cells.
Figure 5 Survival in all patients in the database in whom lymph 
node status is known. Survival is inferior in node-positive patients 
and in patients who are expressors (MAPS+). MAPS adds significantly 
to prognostication in both node-negative and node-positive patients.
Figure 6 Expressional clustering of genes in the MAPS signature 
in a second lung adenocarcinoma database. Survival for these 
groups is shown in a Kaplan-Meier curve with expressors (MAPS+, n = 
52) and non-expressors (MAPS-, n = 32).MacDermed et al. BMC Medical Genomics 2010, 3:16
http://www.biomedcentral.com/1755-8794/3/16
Page 11 of 12
Competing interests
D. Kufe holds equity in Genus Oncology and is a consultant to the company.
Authors' contributions
DMM and NNK designed the study, carried out data analysis and drafted the
manuscript. SPP participated in data analysis and helped draft the manuscript.
DCE carried out ROC analysis and generated ROC curves. CAP participated in
design and coordination of the ROC analysis. LH helped with data collection
and analysis. DWK and RRW coordinated the entire study, designed the con-
cept and helped draft the manuscript. All authors read and approved the final
manuscript.
Acknowledgements
We thank Masha Kocherginsky for her assistance with statistical analysis. 
Research support: NIH Research Project Grant (R01) CA111423 and Lung Can-
cer Research Foundation (RRW). NIH Research Project Grant (R01) CA97098 
(DWK).
Author Details
1The Scripps Research Institute and Scripps Translational Science Institute, 
3344 N. Torrey Pines Court Ste. 300, La Jolla, CA, 92037, USA, 2Department of 
Radiation and Cellular Oncology, The University of Chicago, Duchossois Center 
for Advanced Medicine, 5758 S. Maryland Avenue, MC9006, Chicago, IL 60637, 
USA, 3Department of Radiology, The University of Chicago Medical Center. 
5841 S. Maryland Ave., Chicago, IL 60637, USA and 4Dana-Farber Cancer 
Institute, Harvard Medical School, 44 Binney St., Dana 830, Boston, MA 02115, 
USA
References
1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun 
MJ: Cancer statistics, 2004.  CA Cancer J Clin 2004, 54(1):8-29.
2. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, 
Spitznagel EL, Piccirillo J: Changing epidemiology of small-cell lung 
cancer in the United States over the last 30 years: analysis of the 
surveillance, epidemiologic, and end results database.  J Clin Oncol 
2006, 24(28):4539-4544.
3. Auperin A, Le Pechoux C, Pignon JP, Koning C, Jeremic B, Clamon G, 
Einhorn L, Ball D, Trovo MG, Groen HJ, et al.: Concomitant radio-
chemotherapy based on platin compounds in patients with locally 
advanced non-small cell lung cancer (NSCLC): a meta-analysis of 
individual data from 1764 patients.  Ann Oncol 2006, 17(3):473-483.
4. Tsao MS, Zhu C, Ding K, Strumpf D, Pintilie M, Meyerson M, Seymour L, 
Jurisica I, Shepherd FA: A 15-gene expression signature prognostic for 
survival and predictive for adjuvant chemotherapy benefit in JBR.10 
patients.  J Clin Oncol 2008, 26:. (May 20 suppl; abstr 7510)
5. Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, Yuan A, Cheng CL, Wang 
CH, Terng HJ, Kao SF, et al.: A five-gene signature and clinical outcome in 
non-small-cell lung cancer.  N Engl J Med 2007, 356(1):11-20.
6. Seregni E, Botti C, Lombardo C, Cantoni A, Bogni A, Cataldo I, Bombardieri 
E: Pattern of mucin gene expression in normal and neoplastic lung 
tissues.  Anticancer Res 1996, 16(4B):2209-2213.
7. Li Y, Liu D, Chen D, Kharbanda S, Kufe D: Human DF3/MUC1 carcinoma-
associated protein functions as an oncogene.  Oncogene 2003, 
22(38):6107-6110.
8. Huang L, Ren J, Chen D, Li Y, Kharbanda S, Kufe D: MUC1 cytoplasmic 
domain coactivates Wnt target gene transcription and confers 
transformation.  Cancer Biol Ther 2003, 2(6):702-706.
9. Yin L, Li Y, Ren J, Kuwahara H, Kufe D: Human MUC1 carcinoma antigen 
regulates intracellular oxidant levels and the apoptotic response to 
oxidative stress.  J Biol Chem 2003, 278(37):35458-35464.
10. Ren J, Agata N, Chen D, Li Y, Yu WH, Huang L, Raina D, Chen W, Kharbanda 
S, Kufe D: Human MUC1 carcinoma-associated protein confers 
resistance to genotoxic anticancer agents.  Cancer Cell 2004, 
5(2):163-175.
11. Raina D, Kharbanda S, Kufe D: The MUC1 oncoprotein activates the anti-
apoptotic phosphoinositide 3-kinase/Akt and Bcl-xL pathways in rat 
3Y1 fibroblasts.  J Biol Chem 2004, 279(20):20607-20612.
12. Wei X, Xu H, Kufe D: Human MUC1 oncoprotein regulates p53-
responsive gene transcription in the genotoxic stress response.  Cancer 
Cell 2005, 7(2):167-178.
13. Ohgami A, Tsuda T, Osaki T, Mitsudomi T, Morimoto Y, Higashi T, 
Yasumoto K: MUC1 mucin mRNA expression in stage I lung 
adenocarcinoma and its association with early recurrence.  Ann Thorac 
Surg 1999, 67(3):810-814.
14. Guddo F, Giatromanolaki A, Koukourakis MI, Reina C, Vignola AM, 
Chlouverakis G, Hilkens J, Gatter KC, Harris AL, Bonsignore G: MUC1 
(episialin) expression in non-small cell lung cancer is independent of 
EGFR and c-erbB-2 expression and correlates with poor survival in 
node positive patients.  J Clin Pathol 1998, 51(9):667-671.
15. Khodarev NN, Kataoka Y, Murley JS, Weichselbaum RR, Grdina DJ: 
Interaction of amifostine and ionizing radiation on transcriptional 
patterns of apoptotic genes expressed in human microvascular 
endothelial cells (HMEC).  Int J Radiat Oncol Biol Phys 2004, 60(2):553-563.
16. Weichselbaum RR, Ishwaran H, Yoon T, Nuyten DS, Baker SW, Khodarev N, 
Su AW, Shaikh AY, Roach P, Kreike B, et al.: An interferon-related gene 
signature for DNA damage resistance is a predictive marker for 
chemotherapy and radiation for breast cancer.  Proc Natl Acad Sci USA 
2008, 105(47):18490-18495.
17. Pitroda SP, Khodarev NN, Beckett MA, Kufe DW, Weichselbaum RR: MUC1-
induced alterations in a lipid metabolic gene network predict response 
of human breast cancers to tamoxifen treatment.  Proc Natl Acad Sci USA 
2009, 106(14):5837-5841.
18. Khodarev NN, Pitroda SP, Beckett MA, MacDermed DM, Huang L, Kufe DW, 
Weichselbaum RR: MUC1-induced transcriptional programs associated 
with tumorigenesis predict outcome in breast and lung cancer.  Cancer 
Res 2009, 69(7):2833-2837.
19. Huang L, Chen D, Liu D, Yin L, Kharbanda S, Kufe D: MUC1 oncoprotein 
blocks glycogen synthase kinase 3beta-mediated phosphorylation 
and degradation of beta-catenin.  Cancer Res 2005, 65(22):10413-10422.
20. Khodarev NN, Yu J, Nodzenski E, Murley JS, Kataoka Y, Brown CK, Grdina 
DJ, Weichselbaum RR: Method of RNA purification from endothelial 
cells for DNA array experiments.  Biotechniques 2002, 32(2):. 316, 318, 
320
21. Kimchi ET, Posner MC, Park JO, Darga TE, Kocherginsky M, Karrison T, Hart 
J, Smith KD, Mezhir JJ, Weichselbaum RR, et al.: Progression of Barrett's 
metaplasia to adenocarcinoma is associated with the suppression of 
the transcriptional programs of epidermal differentiation.  Cancer Res 
2005, 65(8):3146-3154.
22. Khodarev NN, Park J, Kataoka Y, Nodzenski E, Hellman S, Roizman B, 
Weichselbaum RR, Pelizzari CA: Receiver operating characteristic 
analysis: a general tool for DNA array data filtration and performance 
estimation.  Genomics 2003, 81(2):202-209.
23. Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, 
Eschrich S, Jurisica I, Giordano TJ, Misek DE, et al.: Gene expression-based 
survival prediction in lung adenocarcinoma: a multi-site, blinded 
validation study.  Nat Med 2008, 14(8):822-827.
24. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C, 
Beheshti J, Bueno R, Gillette M, et al.: Classification of human lung 
carcinomas by mRNA expression profiling reveals distinct 
adenocarcinoma subclasses.  Proc Natl Acad Sci USA 2001, 
98(24):13790-13795.
25. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, Lin L, 
Chen G, Gharib TG, Thomas DG, et al.: Gene-expression profiles predict 
survival of patients with lung adenocarcinoma.  Nat Med 2002, 
8(8):816-824.
26. Metz CE: Basic principles of ROC analysis.  Seminars in Nuclear Medicine 
1978, VIII(4):283-298.
27. Metz CE, Pan X: "Proper" Binormal ROC Curves: Theory and Maximum-
Likelihood Estimation.  J Math Psychol 1999, 43(1):1-33.
28. Yu H: Cdc20: a WD40 activator for a cell cycle degradation machine.  
Mol Cell 2007, 27(1):3-16.
Additional File 3 Table S2. The top two functional networks represented 
by 254 genes with expressional changes associated with MUC1 transfec-
tion.
Additional File 4 Figure S2. The top functional network represented by 
42 selected genes with expressional changes associated with MUC1 trans-
fection and prognostic significance in lung adenocarcinoma patients.
Received: 16 October 2009 Accepted: 6 May 2010 
Published: 6 May 2010
This article is available from: http://www.biomedcentral.com/1755-8794/3/16 © 2010 MacDermed et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. BMC Medical Genomics 2010, 3:16MacDermed et al. BMC Medical Genomics 2010, 3:16
http://www.biomedcentral.com/1755-8794/3/16
Page 12 of 12
29. Kurasawa Y, Earnshaw WC, Mochizuki Y, Dohmae N, Todokoro K: Essential 
roles of KIF4 and its binding partner PRC1 in organized central spindle 
midzone formation.  EMBO J 2004, 23(16):3237-3248.
30. Paris J, Leplatois P, Nurse P: Study of the higher eukaryotic gene 
function CDK2 using fission yeast.  J Cell Sci 1994, 107(Pt 3):615-623.
31. Holt LJ, Krutchinsky AN, Morgan DO: Positive feedback sharpens the 
anaphase switch.  Nature 2008, 454(7202):353-357.
32. Patterson KI, Brummer T, O'Brien PM, Daly RJ: Dual-specificity 
phosphatases: critical regulators with diverse cellular targets.  Biochem 
J 2009, 418(3):475-489.
33. Kittler R, Putz G, Pelletier L, Poser I, Heninger AK, Drechsel D, Fischer S, 
Konstantinova I, Habermann B, Grabner H, et al.: An endoribonuclease-
prepared siRNA screen in human cells identifies genes essential for cell 
division.  Nature 2004, 432(7020):1036-1040.
34. Dairkee SH, Ji Y, Ben Y, Moore DH, Meng Z, Jeffrey SS: A molecular 
'signature' of primary breast cancer cultures; patterns resembling 
tumor tissue.  BMC Genomics 2004, 5(1):47.
35. Karstensen B, Poppelreuther S, Bonin M, Walter M, Iftner T, Stubenrauch F: 
Gene expression profiles reveal an upregulation of E2F and 
downregulation of interferon targets by HPV18 but no changes 
between keratinocytes with integrated or episomal viral genomes.  
Virology 2006, 353(1):200-209.
36. Tedesco D, Zhang J, Trinh L, Lalehzadeh G, Meisner R, Yamaguchi KD, 
Ruderman DL, Dinter H, Zajchowski DA: The ubiquitin-conjugating 
enzyme E2-EPF is overexpressed in primary breast cancer and 
modulates sensitivity to topoisomerase II inhibition.  Neoplasia 2007, 
9(7):601-613.
37. Crawford NP, Alsarraj J, Lukes L, Walker RC, Officewala JS, Yang HH, Lee MP, 
Ozato K, Hunter KW: Bromodomain 4 activation predicts breast cancer 
survival.  Proc Natl Acad Sci USA 2008, 105(17):6380-6385.
38. Whitfield ML, George LK, Grant GD, Perou CM: Common markers of 
proliferation.  Nat Rev Cancer 2006, 6(2):99-106.
39. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette 
T, Pandey A, Chinnaiyan AM: Large-scale meta-analysis of cancer 
microarray data identifies common transcriptional profiles of 
neoplastic transformation and progression.  Proc Natl Acad Sci USA 2004, 
101(25):9309-9314.
40. Zhang YW, Jones TL, Martin SE, Caplen NJ, Pommier Y: Implication of 
checkpoint kinase-dependent up-regulation of ribonucleotide 
reductase R2 in DNA damage response.  J Biol Chem 2009, 
284(27):18085-18095.
41. Raina D, Ahmad R, Joshi MD, Yin L, Wu Z, Kawano T, Vasir B, Avigan D, 
Kharbanda S, Kufe D: Direct Targeting of the Mucin 1 Oncoprotein 
Blocks Survival and Tumorigenicity of Human Breast Carcinoma Cells.  
Cancer Res 2009:5133-5141.
42. Cho WC: Potentially useful biomarkers for the diagnosis, treatment and 
prognosis of lung cancer.  Biomed Pharmacother 2007, 61(9):515-519.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1755-8794/3/16/prepub
doi: 10.1186/1755-8794-3-16
Cite this article as: MacDermed et al., MUC1-associated proliferation signa-
ture predicts outcomes in lung adenocarcinoma patients BMC Medical 
Genomics 2010, 3:16